Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict ...

et al. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid ...

Introduction: We developed and produced a new series of 4,6-diaryl-pyrimidines 9–29 as antiproliferative agents targeting EGFR/VEGFR-2. Methods: The antiproliferative efficacy of the novel targets was ...